• DocMorris H1: revenue rose 13.4% to CHF 599.2 million; net loss narrowed to CHF 53.1 million.
• Adjusted EBITDA loss narrowed to CHF 10.9 million from CHF 28.8 million; IFRS EBITDA loss widened to CHF 20 million on CHF 7.6 million one-offs.
• Germany prescription revenue jumped 38.3% to CHF 147.9 million; active Rx customers increased 15.6% year-on-year.
• Digital Services revenue climbed 71.4%; adjusted EBITDA improved on lower Rx acquisition costs and higher profit contributions from Digital Services.
• Raised 2026 outlook: external revenue growth 9%-13%; adjusted EBITDA loss CHF 10 million-CHF 17.5 million, targeting H2 EBITDA breakeven.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DocMorris AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2385238_en) on August 19, 2026, and is solely responsible for the information contained therein.